Discover MacuMira, a clinically proven technology approved by Health Canada. It uses a device that delivers a microcurrent through closed eyes to target retinal cells and slow the progression of age-related dry macular degeneration (AMD).
It’s for me if…
I have early to intermediate age-related dry macular degeneration.
Contraindications
This treatment should be avoided if you have a pacemaker, a cochlear implant, or if you suffer from severe or uncontrolled glaucoma, multiple sclerosis, or epilepsy.
Initial duration
4 sessions of 32 minutes for the first 10 days.
Cost
500 $ per session.
Prix valide jusqu’au 31 décembre 2026.
MacuMira is the only treatment currently available on the market for age-related dry macular degeneration. This painless technology aims to slow the progression of the condition by acting directly on the cells of the retina to stimulate their regeneration.
Microcurrent stimulation sends pulses through closed eyelids, cleansing the retina and improving visual function in patients with dry macular degeneration.
Retrouvez une vision plus claire et ne laissez pas les symptômes affecter votre qualité de vie. Schedule an appointment with one of our professionals today and discover MacuMira technology. Schedule an appointment with one of our professionals today and discover MacuMira technology.
AMD is a progressive retinal disease affecting the macula, the area responsible for central vision and detail perception. It primarily affects people over 50 and can lead to severe loss of central vision, making it difficult to read, drive and recognize faces.
Eye Am offers specialized exams for early AMD screening, monitoring its progression and implementing personalized treatments to slow or stabilize the disease using technologies like retinal scanning (OCT).
Early signs include loss of clarity in central vision, perception of distorted or wavy lines, difficulty distinguishing fine details and sometimes increased sensitivity to light. A dark spot (scotoma) in the center of the visual field indicates a more advanced stage.
Diagnosis at Eye Am is based on fundus examination, OCT and the Amsler grid. The earlier the screening, the more effective the treatment options are for delaying vision loss.
Treatment depends on the type of AMD. For the dry form, Eye Am offers antioxidant supplements and innovative treatments like MacuMira. For the wet form, anti-VEGF medication injections are used to slow the growth of abnormal blood vessels under the retina.
Close follow-up, dietary adjustments and educational support are essential to maintaining functional vision as long as possible. Eye Am also offers daily living aids like electronic magnifiers and optical adaptations.
MacuMira is a non-invasive treatment offered at Eye Am to slow the progression of dry AMD. It delivers a microcurrent that promotes regeneration of retinal cells and improves microcirculation at the macula level.
This treatment offers an alternative or complement to traditional antioxidant supplementation, extending the period of independent functional vision. Eye Am continuously monitors results and adjusts the protocol based on each patient’s progress.
There is a strong genetic component to AMD: a family history significantly increases the risk of developing the disease, especially in the presence of aggravating factors like smoking, a diet low in antioxidants or high blood pressure.
Eye Am recommends early AMD screening for people with family history, even in the absence of symptoms. Prevention involves controlling modifiable risk factors and maintaining regular optometric follow-up.
Prevention relies on a diet rich in vitamins C and E, zinc and omega-3s, protection against UV and blue light exposure, quitting smoking and managing cardiovascular conditions. Regular physical activity and limiting screen time are also recognized factors in reducing the risk of macular degeneration.
Eye Am offers preventive follow-up including retinal scanning, nutritional advice and recommendations on appropriate protective sunglasses to prevent the onset and progression of AMD.
The risk of AMD increases after age 50 and grows significantly from age 65 onward. Preventive screening is recommended from age 40 for people with risk factors like family history of macular degeneration, smoking or high blood pressure.
Eye Am advocates close follow-up for older adults and offers complementary assessments including retinal scanning from the age of 40 to detect the first clinical signs before symptoms appear.
There is no definitive cure for macular degeneration, but early and multidisciplinary management can significantly slow its progression and maintain quality of visual life. Current treatments can stabilize central vision and delay the disease’s advancement.
Eye Am follows each patient individually with therapies adjusted based on the response obtained, with the goal of maximizing functional vision and supporting adaptation to visual changes.
Dry AMD accounts for approximately 85% of cases and progresses slowly through gradual atrophy of the macula. Wet (exudative) AMD is more aggressive: it is characterized by the growth of abnormal blood vessels under the retina, causing hemorrhages and rapid distortion of central vision.
Eye Am has specific protocols for the dry form, including MacuMira and supplementation, and works in collaboration with ophthalmologists who provide anti-VEGF injections for the wet form. The clinical distinction between the two forms is essential to tailor the treatment and optimize the visual prognosis.
Follow-up includes regular OCT and fundus exams, central vision assessments, prescription of appropriate dietary supplements and monitoring of risk factors associated with macular degeneration. Eye Am maintains continuous documentation and intervenes quickly in the event of unfavorable progression.
In the case of significant vision loss, the clinic offers support toward specialized visual aids and collaboration with rehabilitation structures to preserve the patient’s independence and quality of life.
AMD can affect the ability to drive by reducing central vision, altering contrast perception and creating zones of blurred or spotty vision in the visual field. These changes make it difficult to read road signs, judge distances and detect obstacles.
Eye Am regularly evaluates the impact of AMD on functional vision and advises patients on their driving ability. Optical adjustments and visual aids can extend the ability to drive safely, in collaboration with SAAQ requirements.
